Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials. (Q48317531)

10 February 2018

meta-analysis

0 references

title

Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials. (English)

1 reference

10 February 2018

2

Ilaria Dicembrini

1 reference

10 February 2018

Matteo Monami

1

1 reference

10 February 2018

Besmir Nreu

3

1 reference

10 February 2018

Francesco Andreozzi

4

1 reference

10 February 2018

Giorgio Sesti

5

1 reference

10 February 2018

Edoardo Mannucci

6

1 reference

10 February 2018

publication date

20 September 2017

1 reference

10 February 2018

published in

Acta Diabetologica

1 reference

10 February 2018

volume

54

1 reference

10 February 2018

page(s)

1101-1114

1 reference

10 February 2018

issue

12

1 reference

10 February 2018

https://scigraph.springernature.com/pub.10.1007/s00592-017-1054-2

exact match

0 references

cites work

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Pharmacologic management of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

PPAR-α as a key nutritional and environmental sensor for metabolic adaptation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised c

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Effectiveness of lifestyle-based weight loss interventions for adults with type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Fasting and post-prandial glycemia and their correlation with glycated hemoglobin in Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Incretins: their physiology and application in the treatment of diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Effects of aging on insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Identification of predictors of response to basal insulin and DPP4 inhibitors in patients with type 2 diabetes failing to other therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-017-1054-2

10.1007/S00592-017-1054-2

21 January 2018

Identifiers

DOI

1 reference

10 February 2018

PubMed ID

28932989

1 reference

10 February 2018